Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the BEAM Therapeutics conference call. At this time, all participants are in a listen-only mode. There will be a question and answer session at the end. Please be advised that this call is being recorded at BEAM's request. I would now like to turn the call over to Holly Manning, Vice President of Investor Relations and External Communications. Thank you, operators. Good morning, everyone, and welcome to BEAM's conference call to review third quarter 2024 business updates, including abstracts accepted for presentation at the American Society of Hematology Annual Meeting. You can access slides for today's call by going to the investor section of our website, beamtx.com. With me on the call today with prepared remarks are John Evans, our Chief Executive Officer, Dr. Giuseppe Pino Taramella, our president, and Dr. Amy Simon, our chief medical officer. Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors. including those set forth in the risk factor section of our most recent annual report on Form 10-K, as updated by our quarterly reports on Form 10-Q and any other filings that we may make with the FCC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, BEAM specifically disclaims any obligation to update or revise any forward-looking statem...